Indeed, concerns regarding the skewing of T cell responses towards Th17-dominated responses by the TLR2 ligand lipoprotein OspA, and the potential for this to contribute to the development of autoimmune diseases, have stopped the commercialization of a Lyme disease vaccine containing this TLR2 ligand [28]. Here, TLR2 is linked to Lyme disease.